AU Patent

AU2011307306A1 — Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases

Assigned to Exelixis Inc · Expires 2013-05-02 · 13y expired

What this patent protects

This invention is directed to the treatment of cancer, particularly castration- resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.

USPTO Abstract

This invention is directed to the treatment of cancer, particularly castration- resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: AU2011307306A1
Jurisdiction: AU
Classification: —
Expires: 2013-05-02
Drug substance claim: No
Drug product claim: No
Assignee: Exelixis Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.